JANX

insider transactions

Janux Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-20.1K

5.0K buy · 25.1K sell

Net value · 365d

-$284.8K

$62.3K in · $347.1K out

Sentiment · 365d

Net selling

15% buying · 85% selling

Open-market trades · 365d

5.0K buy · 25.1K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 11, 26

Jake Simson

Director

$0

15.5K sh

Own New
Grant·A
Jun 11, 26

Jake Simson

Director

$0

5.5K sh

Own +88%
Grant·A
Jun 11, 26

Winston Kung

Director

$0

15.5K sh

Own New
Grant·A
Jun 11, 26

Winston Kung

Director

$0

5.5K sh

Own +88%
Grant·A
Jun 11, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$0

15.5K sh

Own New
Grant·A
Jun 11, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$0

5.5K sh

Own +88%
Grant·A
Jun 11, 26

Natasha Hernday

Director

$0

15.5K sh

Own New
Grant·A
Jun 11, 26

Natasha Hernday

Director

$0

5.5K sh

Own +55%
Grant·A
Jun 11, 26

Vickie L Capps

Director

$0

15.5K sh

Own New
Grant·A
Jun 11, 26

Vickie L Capps

Director

$0

5.5K sh

Own +7%
Grant·A
Jun 11, 26

Ronald W Barrett

Director

$0

15.5K sh

Own New
Grant·A
Jun 11, 26

Ronald W Barrett

Director

$0

5.5K sh

Own +88%
Grant·A
Jun 10, 26

Vickie L Capps

Director

$0

15.0K sh

Own +53%
Sell·S
Jun 2, 26

Janeen Noel Doyle

Chief Corp. & Bus. Dev. Ofcr

$56.9K

4.1K sh · $14.03

Own -5%
Grant·A
May 21, 26

Natasha Hernday

Director

$0

3.6K sh

Own +40%
Sell·S
May 11, 26

Maria Dobek KEY

Vice President, Accounting

$28.9K

2.0K sh · $14.17

Own -6%
Buy·P
Mar 10, 26

Vickie L Capps

Director

$29.9K

2.4K sh · $12.45

Own +10%
Buy·P
Mar 10, 26

Vickie L Capps

Director

$1.2K

100 sh · $12.44

Own +0%
Buy·P
Mar 9, 26

Vickie L Capps

Director

$31.2K

2.5K sh · $12.48

Own +11%
Grant·A
Feb 2, 26

William Go

Chief Medical Officer

$0

154.0K sh

Own New
Grant·A
Feb 2, 26

William Go

Chief Medical Officer

$0

44.0K sh

Own New
Grant·A
Jan 2, 26

Zachariah Mciver

Chief Medical Officer

$0

101.5K sh

Own New
Grant·A
Jan 2, 26

Zachariah Mciver

Chief Medical Officer

$0

29.0K sh

Own +125%
Sell·S
Jan 2, 26

Zachariah Mciver

Chief Medical Officer

$37.3K

2.7K sh · $13.73

Own -10%
Grant·A
Jan 2, 26

Charles M. Winter

Chief Technical Officer

$0

100.1K sh

Own New
Grant·A
Jan 2, 26

Charles M. Winter

Chief Technical Officer

$0

28.6K sh

Own +37%
Sell·S
Jan 2, 26

Charles M. Winter

Chief Technical Officer

$33.0K

2.4K sh · $13.73

Own -3%
Sell·S
Jan 2, 26

Andrew Hollman Meyer

Chief Business Officer

$25.8K

1.9K sh · $13.73

Own -2%
Grant·A
Jan 2, 26

Janeen Noel Doyle

Chief Corp. & Bus. Dev. Ofcr

$0

126.0K sh

Own New
Grant·A
Jan 2, 26

Janeen Noel Doyle

Chief Corp. & Bus. Dev. Ofcr

$0

36.0K sh

Own +82%
Grant·A
Jan 2, 26

Maria Dobek KEY

Vice President, Accounting

$0

42.6K sh

Own New
Grant·A
Jan 2, 26

Maria Dobek KEY

Vice President, Accounting

$0

18.9K sh

Own +123%
Sell·S
Jan 2, 26

Maria Dobek KEY

Vice President, Accounting

$20.1K

1.5K sh · $13.73

Own -9%
Grant·A
Jan 2, 26

Thomas Diraimondo

Chief Scientific Officer

$0

109.9K sh

Own New
Grant·A
Jan 2, 26

Thomas Diraimondo

Chief Scientific Officer

$0

31.4K sh

Own +25%
Sell·S
Jan 2, 26

Thomas Diraimondo

Chief Scientific Officer

$34.4K

2.5K sh · $13.73

Own -2%
Grant·A
Jan 2, 26

David Alan Campbell KEY

President and CEO

$0

338.1K sh

Own New
Grant·A
Jan 2, 26

David Alan Campbell KEY

President and CEO

$0

96.6K sh

Own +34%
Sell·S
Jan 2, 26

David Alan Campbell KEY

President and CEO

$110.8K

8.1K sh · $13.73

Own -3%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 11, 2026	Jake Simson	Director	Grant A	15.5K	New	—	$0
Jun 11, 2026	Jake Simson	Director	Grant A	5.5K	+88%	—	$0
Jun 11, 2026	Winston Kung	Director	Grant A	15.5K	New	—	$0
Jun 11, 2026	Winston Kung	Director	Grant A	5.5K	+88%	—	$0
Jun 11, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Grant A	15.5K	New	—	$0
Jun 11, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund II, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Grant A	5.5K	+88%	—	$0
Jun 11, 2026	Natasha Hernday	Director	Grant A	15.5K	New	—	$0
Jun 11, 2026	Natasha Hernday	Director	Grant A	5.5K	+55%	—	$0
Jun 11, 2026	Vickie L Capps	Director	Grant A	15.5K	New	—	$0
Jun 11, 2026	Vickie L Capps	Director	Grant A	5.5K	+7%	—	$0
Jun 11, 2026	Ronald W Barrett	Director	Grant A	15.5K	New	—	$0
Jun 11, 2026	Ronald W Barrett	Director	Grant A	5.5K	+88%	—	$0
Jun 10, 2026	Vickie L Capps	Director	Grant A	15.0K	+53%	—	$0
Jun 2, 2026	Janeen Noel Doyle	Chief Corp. & Bus. Dev. Ofcr	Sell S	4.1K	-5%	$14.03	$56.9K
May 21, 2026	Natasha Hernday	Director	Grant A	3.6K	+40%	—	$0
May 11, 2026	Maria Dobek KEY	Vice President, Accounting	Sell S	2.0K	-6%	$14.17	$28.9K
Mar 10, 2026	Vickie L Capps	Director	Buy P	2.4K	+10%	$12.45	$29.9K
Mar 10, 2026	Vickie L Capps	Director	Buy P	100	+0%	$12.44	$1.2K
Mar 9, 2026	Vickie L Capps	Director	Buy P	2.5K	+11%	$12.48	$31.2K
Feb 2, 2026	William Go	Chief Medical Officer	Grant A	154.0K	New	—	$0
Feb 2, 2026	William Go	Chief Medical Officer	Grant A	44.0K	New	—	$0
Jan 2, 2026	Zachariah Mciver	Chief Medical Officer	Grant A	101.5K	New	—	$0
Jan 2, 2026	Zachariah Mciver	Chief Medical Officer	Grant A	29.0K	+125%	—	$0
Jan 2, 2026	Zachariah Mciver	Chief Medical Officer	Sell S	2.7K	-10%	$13.73	$37.3K
Jan 2, 2026	Charles M. Winter	Chief Technical Officer	Grant A	100.1K	New	—	$0
Jan 2, 2026	Charles M. Winter	Chief Technical Officer	Grant A	28.6K	+37%	—	$0
Jan 2, 2026	Charles M. Winter	Chief Technical Officer	Sell S	2.4K	-3%	$13.73	$33.0K
Jan 2, 2026	Andrew Hollman Meyer	Chief Business Officer	Sell S	1.9K	-2%	$13.73	$25.8K
Jan 2, 2026	Janeen Noel Doyle	Chief Corp. & Bus. Dev. Ofcr	Grant A	126.0K	New	—	$0
Jan 2, 2026	Janeen Noel Doyle	Chief Corp. & Bus. Dev. Ofcr	Grant A	36.0K	+82%	—	$0
Jan 2, 2026	Maria Dobek KEY	Vice President, Accounting	Grant A	42.6K	New	—	$0
Jan 2, 2026	Maria Dobek KEY	Vice President, Accounting	Grant A	18.9K	+123%	—	$0
Jan 2, 2026	Maria Dobek KEY	Vice President, Accounting	Sell S	1.5K	-9%	$13.73	$20.1K
Jan 2, 2026	Thomas Diraimondo	Chief Scientific Officer	Grant A	109.9K	New	—	$0
Jan 2, 2026	Thomas Diraimondo	Chief Scientific Officer	Grant A	31.4K	+25%	—	$0
Jan 2, 2026	Thomas Diraimondo	Chief Scientific Officer	Sell S	2.5K	-2%	$13.73	$34.4K
Jan 2, 2026	David Alan Campbell KEY	President and CEO	Grant A	338.1K	New	—	$0
Jan 2, 2026	David Alan Campbell KEY	President and CEO	Grant A	96.6K	+34%	—	$0
Jan 2, 2026	David Alan Campbell KEY	President and CEO	Sell S	8.1K	-3%	$13.73	$110.8K

About JANX insider trading

This page tracks insider transactions for Janux Therapeutics, Inc. (JANX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.